The new Covid "cure" is not tested, says the doctor
The drug is experimental and the profit still needs to be tested.
The scientific method is a very important aspect of biomedical research. From the hypothesis, tests, the conclusion, science must have ways to get an idea and test if this idea can help people. The medical system relies heavily on this type of research. Testing if drugs or therapies can help eradicate the disease or improve the life of a patient is an integral part of the provision of science and medicine ahead. This is often in contradiction with the world of business or public opinion because there is often the desire to come to the conclusions quickly, especially in case of major need that must be satisfied.
This plays in the public domain with respect to REGNERON experimental drug that has been given to the chair during the weekend. (Read it, and cross this pandemic with your healthiest, do not miss theseWithout signs that you have already had coronavirus.)
Refuge
The drug is still experimental
The biotechnology company behind the medicine has just been applied to the American Food and Drug Administration for emergency authorization. "Under our agreement with the US government for the initial doses of REGN-COV2, if UN EU is granted to the Government is committed to making these doses at the disposal of the American people at no cost and would be responsible for their distribution", a declaration on their website said. "At that time, doses are available for about 50,000 patients and we anticipate doses available on 300,000 patients in the coming months.
The use of the drug on the president was experimental and, although no deleterious result seems to have taken place, the advantage must still be tested. In theory, it is an obvious choice of antibodies to attack the virus. It blocks the virus ability to enter the patient's cells, which minimizes the patient's symptoms and should be recovered. The problem is that the theory does not always lead to a viable, safe medicine. The ability of a drug to undergo randomized controlled trials where it is tested against placebo is an important step in determining its success. There are countless variables that need to be counted such as age, gender, medical problems, even when a drug is administered that can tilt the results of a medicine positively or negatively.
The fact that Regeneron's REGN-COV2 had a beneficial result for a patient, although a very important patient, does not mean that the drug is a success. It must also be said that if it does not work on the president, it does not mean it's a failure. The scientific method does not determinate the efficiency based on a patient, but on statistical calculations of a large group of patients.
Given the fact that the REGN-COV2 is still tested, it could be said that it is unfair to the manufacturer of drugs and physicians and patients enrolled in studies across the country to put such a focus on the drug. 'actual hour. Efforts, such as giving the medicine for free, could push it artificially on the market. This can prevent the routes necessary to ensure its safety, which could be detrimental to the drug itself. If a small problem can not be treated before a large-scale administration, a small problem that can be corrected can be interpreted as a complete failure. Although REGN-COV2 is the answer to the CVIV-19 crisis, only after exhaustive research will be the health care community gives its full support.
